内隐自尊改善与新型协同干预延长抗抑郁效应相关
该研究是对既往随机对照试验的二次分析,纳入154名18-60岁难治性单相抑郁且外显自尊低于常模的成人,比较氯胺酮联合自动化自我关联训练(ASAT)与两个对照组的疗效。结果显示,氯胺酮+ASAT组治疗后内隐联想测试(IAT)评分提示更积极自我关联,且IAT评分中介了该组第30天抑郁改善。
要点
- IAT评分与所有治疗组急性期MADRS评分变化相关(p=0.001)。
- 仅氯胺酮+ASAT组中IAT评分中介第30天抑郁改善(组别×IAT交互β=-0.201;p=0.049)。
核心结论
- 改变内隐自我价值可能是氯胺酮+ASAT联合治疗发挥持久抗抑郁获益的关键机制之一。
研究设计与样本
- 二次分析 of 一项双盲、平行臂随机对照试验,纳入154名18-60岁难治性单相抑郁且外显自尊低于常模的成人。
- 受试者随机接受单次氯胺酮输注(0.5 mg/kg)后4天ASAT(约30-40分钟/天)、缺活性药物或缺活性行为成分的对照方案。
- 使用内隐联想测试(IAT)评估自我相关刺激与负性概念关联强度,线性回归分析组别、治疗后IAT评分与急性及延长临床结局的关系。
主要发现
- 所有治疗臂中IAT评分与急性期MADRS评分变化百分比相关(p=0.001)。
- 仅氯胺酮+ASAT组中IAT评分中介第30天抑郁改善(组别×IAT交互项β=-0.201;p=0.049)。
临床怎么用
- 在氯胺酮治疗后塑性窗口内联合ASAT可能通过改善内隐自我关联延长抗抑郁效果。
- 内隐认知指标或可作为评估此类协同干预靶点 engagement 的参考。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In a previously published randomized controlled trial, automated self-association training (ASAT), a novel digital intervention, was found to extend the rapid antidepressant effect of a single infusion of ketamine for at least 30 days. In this secondary analysis, we aimed to understand the potential role of implicit self-esteem in the combined antidepressant effect of ketamine and ASAT training, by investigating the novel synergistic treatment's effects on implicit self-associations and their relation to symptom improvement. METHODS: A total of 154 adults (ages 18-60) with treatment-resistant unipolar depression and lower-than-normative explicit self-esteem were randomized in a double-blind, parallel-arm design to receive one of three treatment allocations: an active/active treatment combination consisting of one infusion of ketamine (0.5 mg/kg) followed by four days of ASAT ( ~ 30-40 min/day), or one of two control arms that lacked either the active drug or the active behavioral component. The Implicit Association Test (IAT) was used to behaviorally assess the strength of association between self-related stimuli and negative concepts. Linear regression models were used to test the relationship between group assignment, IAT scores acquired immediately post-treatment, and both acute and extended clinical outcomes (% change in Montgomery-Asberg Depression Rating Scale scores, relative to pre-treatment baseline) in the trial. RESULTS: The group assigned to ketamine + ASAT intervention, compared to the other groups, had a pattern of IAT scores indicating more positive self-associations immediately after treatment relative to the control arms (F(1, 131) = 3.979; p = 0.048). In regression models, IAT scores tracked with concurrent (acute post-treatment) % change in MADRS scores across all treatment arms (p = 0.001), and mediated more extended (Day 30) depression improvements specifically for the ketamine+ASAT arm (group * IAT interaction term: β = -0.201; p = 0.049). DISCUSSION: Our findings suggest that changing implicit self-worth during a post-ketamine 'plasticity window' is one key mechanism whereby the novel ketamine+ASAT treatment combination exerts its antidepressant benefit, confirming the intended treatment target at the level of implicit cognition. Future studies should seek to further enhance the reliability of the biobehavioral intervention's impact on implicit cognition, as this mechanism appears linked to the intervention's enduring clinical benefits.
引用
- Eken HN, Spotts C, Panny B, et al. Improved implicit self-esteem is associated with extended antidepressant effects following a novel synergistic intervention. Mol Psychiatry. 2024. PMID: 38755245. doi:10.1038/s41380-024-02564-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。